ERBB2 and neoplasm: They explored the first-generation anti-CD19, anti-mesothelin, and anti-HER2 CARs in the THP-1 macrophage cell line and discovered that CAR-Ms could selectively phagocytose and eliminate cognate antigen-bearing tumor cells (Snyder and Gill, 2023).